Photo of Peter Chang,  MD, MPH

Peter Chang, MD, MPH

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 667-4075
Fax: (617) 667-7292


pchang@bidmc.harvard.edu

Peter Chang, MD, MPH

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

  • Assistant Professor, Surgery, Harvard Medical School
  • Director, Prostate Cancer Care Center, Surgery, Beth Israel Deaconess Medical Center

DF/HCC PROGRAM AFFILIATION

Research Abstract

I am a Urologic Oncologist with a clinical and research focus on prostate cancer. Currently, I am an Instructor in Surgery at Harvard Medical School, and Director of the Prostate Cancer Care Center at the Beth Israel Deaconess Medical Center. I am a leader in the assessment and management of health-related quality of life (HRQOL) using patient-reported outcomes (PROs), and have a particular interest in the adaptation and implementation of PROs to directly improve patient evaluation and communication in clinical practice. I developed the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) with the goal of allowing HRQOL to be assessed using PROs at the point of care. I am a co-leader of the PROST-QA consortium, a multicenter, prospective cohort of 1,201 men treated for localized prostate cancer followed longitudinally for clinical and HRQOL outcomes. My prostate cancer outcomes research focuses on investigating the factors predicting HRQOL after prostate cancer treatment and evaluating HRQOL in the advanced disease setting. As a practicing minimally invasive urologic surgeon, I also study HRQOL and surgical outcomes following minimally invasive kidney cancer and bladder cancer surgery.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Delto JC, Fleishman A, Chang P, Jiang DD, Hyde S, McAnally K, Crociani C, Jamil M, Patel HD, Pavlinec J, Budzyn J, Durant A, Eilender B, Gordon AO, Huang MM, Pierorazio PM, Raman JD, Rogers C, Su LM, Wagner AA. Perioperative Aspirin Use is Associated with Bleeding Complications during Robotic Partial Nephrectomy. J Urol 2021. PubMed
  • Chang P, Wagner AA, Regan MM, Smith JA, Saigal CS, Litwin MS, Hu JC, Cooperberg MR, Carroll PR, Klein EA, Kibel AS, Andriole GL, Han M, Partin AW, Wood DP, Crociani CM, Greenfield TK, Patil D, Hembroff LA, Davis K, Stork L, Spratt DE, Wei JT, Sanda MG. Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The PROST-QA/RP2 Consortium. J Urol 2021. PubMed
  • Stensland KD, Chang P, Jiang D, Canes D, Berkenwald A, Waisman A, Robinson K, Brat G, Crociani C, Mcanally K, Hyde S, Holliday B, Mechaber J, Baraka A, Moinzadeh A, Wagner AA. Reducing postoperative opioid pill prescribing via a quality improvement approach. Int J Qual Health Care 2021. PubMed
  • Monfared S, Fleishman A, Korets R, Chang P, Wagner A, Bubley G, Kaplan I, Olumi AF, Gershman B. The impact of pretreatment PSA on risk stratification in men with Gleason 6 prostate cancer: Implications for active surveillance. Urol Oncol 2021. PubMed
  • Reitblat C, Fleishman A, Kaplan IA, Stensland KD, D'Amico AV, Olumi AF, Wagner AA, Chang PK, Kim SP, Korets R, Gershman B. Radical prostatectomy versus external beam radiation therapy for high-grade, clinically localized prostate cancer: Emulation of a target clinical trial. Urol Oncol 2021. PubMed
  • McKay RR, Xie W, Ye H, Fennessy FM, Zhang Z, Lis R, Calagua C, Rathkopf D, Laudone VP, Bubley GJ, Einstein DJ, Chang PK, Wagner AA, Parsons JK, Preston MA, Kilbridge K, Chang SL, Choudhury AD, Pomerantz MM, Trinh QD, Kibel AS, Taplin ME. Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer. J Urol 2021. PubMed
  • Unadkat P, Fleishman A, Olumi AF, Wagner A, Chang P, Kim SP, Korets R, Gershman B. Contemporary Incidence and Predictors of Occult Inguinal Lymph Node Metastases in Men with Clinically Node-Negative (cN0) Penile Cancer. Urology 2021. PubMed
  • McKay RR, Berchuck J, Kwak L, Xie W, Silver R, Bubley GJ, Chang PK, Wagner A, Zhang Z, Kibel AS, Taplin ME. Outcomes Post Neoadjuvant Intense Hormone Therapy and Surgery for Patients with High-Risk Localized Prostate Cancer: Results of a Pooled Analysis of Contemporary Clinical Trials. J Urol 2021. PubMed
  • Metcalf MR, Cheaib JG, Biles MJ, Patel HD, Peña VN, Chang P, Wagner AA, McKiernan JM, Pierorazio PM. Outcomes of Active Surveillance for Young Patients with Small Renal Masses: Prospective Data from the DISSRM Registry. J Urol 2020. PubMed
  • Berry DL, Hong F, Blonquist TM, Halpenny B, Xiong N, Filson CP, Master VA, Sanda MG, Chang P, Chien GW, Jones RA, Krupski TL, Wolpin S, Wilson L, Hayes JH, Trinh QD, Sokoloff M. Decision regret, adverse outcomes, and treatment choice in men with localized prostate cancer: Results from a multi-site randomized trial. Urol Oncol 2020. PubMed
  • Lourenço DB, Amaral BS, Alfer-Junior W, Vasconcellos A, Russo F, Sanchez-Salas R, Bianco B, Wagner AA, Chang P, Moschovas MC, Lemos GC, Carneiro A. Portuguese version of the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP): psychometric validation and prospective application for early functional outcomes at a single institution. BMC Urol 2020; 20:163. PubMed
  • Geiger S, Kocher N, Illinsky D, Xylinas E, Chang P, Dewey L, Wagner AA, Petros F, Matin SF, Tobert C, Tracy C, Patard PM, Roumiguie M, Monteiro LL, Kassouf W, Raman JD. Comparison of the Comprehensive Complication Index and Clavien-Dindo systems in predicting perioperative outcomes following radical nephroureterectomy. Transl Androl Urol 2020; 9:1780-1785. PubMed
  • Althaus AB, Chang P, Mao J, Olugbade K, Taylor K, Dewey L, Percy A, Crociani C, McNally K, Wagner AA. Patient-Reported Quality of Life and Convalescence after Minimally Invasive Kidney Cancer Surgery. Urology 2020. PubMed
  • Storås AH, Sanda MG, Garin O, Chang P, Patil D, Crociani C, Suarez JF, Cvancarova M, Loge JH, Fosså SD. A prospective study of patient reported urinary incontinence among American, Norwegian and Spanish men 1 year after prostatectomy. Asian J Urol 2020; 7:161-169. PubMed
  • Srivastava A, Patel HD, Gupta M, Joice GA, Schwen Z, Alam R, Gorin MA, Johnson MH, Trock BJ, Chang P, Wagner AA, McKiernan JM, Allaf ME, Pierorazio PM. The incidence, predictors, and survival of disappearing small renal masses on active surveillance. Urol Oncol 2019. PubMed
  • Delto JC, Chang P, Hyde S, McAnally K, Crociani C, Wagner AA. Eliminating pseudoaneurysm and urine leak after robotic partial nephrectomy: results using the early unclamping technique. Urology 2019. PubMed
  • McKay RR, Ye H, Xie W, Lis R, Calagua C, Zhang Z, Trinh QD, Chang SL, Harshman LC, Ross AE, Pienta KJ, Lin DW, Ellis WJ, Montgomery B, Chang P, Wagner AA, Bubley GJ, Kibel AS, Taplin ME. Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. J Clin Oncol 2019; 37:923-931. PubMed
  • Sotimehin AE, Patel HD, Alam R, Gorin MA, Johnson MH, Chang P, Wagner AA, McKiernan JM, Allaf ME, Pierorazio PM. Selecting Patients with Small Renal Masses for Active Surveillance: A Domain-Based Score from a Prospective Cohort Study. J Urol 2019. PubMed
  • Gupta M, Alam R, Patel HD, Semerjian A, Gorin MA, Johnson MH, Chang P, Wagner AA, McKiernan JM, Allaf ME, Pierorazio PM. Use of delayed intervention for small renal masses initially managed with active surveillance. Urol Oncol 2019; 37:18-25. PubMed
  • Hennigan ST, Trostel SY, Terrigino NT, Voznesensky OS, Schaefer RJ, Whitlock NC, Wilkinson S, Carrabba NV, Atway R, Shema S, Lake R, Sweet AR, Einstein DJ, Karzai F, Gulley JL, Chang P, Bubley GJ, Balk SP, Ye H, Sowalsky AG. Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer. JCO Precis Oncol 2019. PubMed
  • Wilson LS, Blonquist TM, Hong F, Halpenny B, Wolpin S, Chang P, Filson CP, Master VA, Sanda MG, Chien GW, Jones RA, Krupski TL, Berry DL. Assigning value to preparation for prostate cancer decision making: a willingness to pay analysis. BMC Med Inform Decis Mak 2019; 19:6. PubMed
  • Chang P, Renehan P, Taylor KN, Dewey LE, McAnally KC, Hyde S, Crociani CM, Carneiro A, Beaule LT, Wagner AA. Societal costs of localized renal cancer surgery. Can J Urol 2018; 25:9401-9406. PubMed
  • Alam R, Patel HD, Osumah T, Srivastava A, Gorin MA, Johnson MH, Trock BJ, Chang P, Wagner AA, McKiernan JM, Allaf ME, Pierorazio PM. Comparative effectiveness of management options for patients with small renal masses: a prospective cohort study. BJU Int 2018. PubMed
  • Mihalcik SA, Chipman JJ, Sanda MG, Regan MM, Kaplan ID, Wagner AA, Crociani CM, Chang P, . Predicting erectile function following external beam radiation therapy or brachytherapy for prostate cancer using EPIC-CP. 2018. PubMed
  • McKay RR, Montgomery B, Xie W, Zhang Z, Bubley GJ, Lin DW, Preston MA, Trinh QD, Chang P, Wagner AA, Mostaghel EA, Kantoff PW, Nelson PS, Kibel AS, Taplin ME. Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. Prostate Cancer Prostatic Dis 2017. PubMed
  • Uzosike AC, Patel HD, Alam R, Schwen ZR, Gupta M, Gorin MA, Johnson MH, Gausepohl H, Riffon MF, Trock BJ, Chang P, Wagner AA, McKiernan JM, Allaf ME, Pierorazio PM. Growth Kinetics of Small Renal Masses on Active Surveillance: Variability and Results from the DISSRM Registry. J Urol 2017. PubMed
  • Berry DL, Hong F, Blonquist TM, Halpenny B, Filson CP, Master VA, Sanda MG, Chang P, Chien GW, Jones RA, Krupski TL, Wolpin S, Wilson L, Hayes JH, Trinh QD, Sokoloff M, Somayaji P. Decision Support with the Personal Patient Profile-Prostate: A Multi-Center Randomized Trial. J Urol 2017. PubMed
  • Gay HA, Sanda MG, Liu J, Wu N, Hamstra DA, Wei JT, Dunn RL, Klein EA, Sandler HM, Saigal CS, Litwin MS, Kuban DA, Hembroff L, Regan MM, Chang P, , Michalski JM. External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life. Int J Radiat Oncol Biol Phys 2017; 98:304-317. PubMed
  • Chang P, Regan MM, Ferrer M, Guedea F, Patil D, Wei JT, Hembroff LA, Michalski JM, Saigal CS, Litwin MS, Hamstra DA, Kaplan ID, Ciezki JP, Klein EA, Kibel AS, Sandler HM, Dunn RL, Crociani CM, Sanda MG, . Relief of Urinary Symptom Burden after Primary Prostate Cancer Treatment. J Urol 2016. PubMed
  • Lee JY, Daignault-Newton S, Heath G, Scarlett S, Sanda MG, Chang P, Regan MM, Michalski JM, Sandler HM, Feng FY, Kuban DA, Zietman AL, Ciezki JP, Kaplan ID, Crociani C, McLaughlin WP, Mantz CA, Finkelstein SE, Suy S, Collins SP, Garin O, Ferrer M, Hamstra DA, Spratt DE. Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding. Int J Radiat Oncol Biol Phys 2016. PubMed
  • Dovirak O, Mao J, Taylor K, Chang P, Wagner AA. How to Quantify Recovery After Laparoscopic Adrenalectomy: An Assessment of Patient-reported Health-related Quality of Life. Surg Laparosc Endosc Percutan Tech 2016; 26:290-4. PubMed
  • Wagner AA, Cheng PJ, Carneiro A, Dovirak O, Khosla A, Taylor KN, Crociani CM, McAnally KC, Percy A, Dewey LE, Sanda MG, Chang P. Clinical Use of EPIC for Clinical Practice (EPIC-CP) to Assess Patient-Reported Prostate Cancer Quality-of-Life Following Robot-Assisted Radical Prostatectomy. J Urol 2016. PubMed
  • Storås AH, Sanda MG, Boronat OG, Chang P, Patil D, Crociani C, Suarez JF, Cvancarova M, Loge JH, Fosså SD. Erectile Dysfunction and Sexual Problems Two to Three Years After Prostatectomy Among American, Norwegian, and Spanish Patients. Clin Genitourin Cancer 2016; 14:e265-73. PubMed
  • Patel HD, Riffon MF, Joice GA, Johnson MH, Chang P, Wagner AA, McKiernan JM, Trock BJ, Allaf ME, Pierorazio PM. A Prospective, Comparative Study of Quality of Life among Patients with Small Renal Masses choosing Active Surveillance and Primary Intervention. J Urol 2016. PubMed
  • Wolpin S, Halpenny B, Sorrentino E, Stewart M, McReynolds J, Cvitkovic I, Chang P, Berry D. Usability Testing the "Personal Patient Profile-Prostate" in a Sample of African American and Hispanic Men. Comput Inform Nurs 2016. PubMed
  • Quintana L, Ward A, Gerrin SJ, Genega E, Rosen S, Sanda MG, Wagner AA, Chang P, DeWolf WC, Ye H. Gleason Misclassification Rate is Independent of Number of Biopsy Cores in Systematic Biopsy. Urology 2016. PubMed
  • Danzig MR, Chang P, Wagner AA, Allaf ME, McKiernan JM, Pierorazio PM. Active Surveillance for Small Renal Masses: A Review of the Aims and Preliminary Results of the DISSRM Registry. Current Urology Reports 2016; 17:4. PubMed
  • Althaus AB, Dovirak O, Chang P, Taylor KN, O'Halloran TD, Wagner AA. Aspirin and clopidogrel during robotic partial nephrectomy, is it safe? Can J Urol 2015; 22:7984-9. PubMed
  • Danzig MR, Ghandour RA, Chang P, Wagner AA, Pierorazio PM, Allaf ME, McKiernan JM. Active Surveillance is Superior to Radical Nephrectomy and Equivalent to Partial Nephrectomy for Preserving Renal Function in Patients with Small Renal Masses: Results from the DISSRM Registry. J Urol 2015. PubMed
  • Carneiro A, Sasse AD, Wagner AA, Peixoto G, Kataguiri A, Neto AS, Bianco BA, Chang P, Pompeo AC, Tobias-Machado M. Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis. World J Urol 2015; 33:1281-9. PubMed
  • Pierorazio PM, Johnson MH, Ball MW, Gorin MA, Trock BJ, Chang P, Wagner AA, McKiernan JM, Allaf ME. Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry. Eur Urol 2015. PubMed
  • Chen RC, Chang P, Vetter RJ, Lukka H, Stokes WA, Sanda MG, Watkins-Bruner D, Reeve BB, Sandler HM. Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials. Journal of the National Cancer Institute 2014. PubMed
  • Chipman JJ, Sanda MG, Dunn RL, Wei JT, Litwin MS, Crociani CM, Regan MM, Chang P, . Measuring and predicting prostate cancer related quality of life changes using EPIC for clinical practice. J Urol 2014; 191:638-45. PubMed
  • Chang P, Szymanski KM, Dunn RL, Chipman JJ, Litwin MS, Nguyen PL, Sweeney CJ, Cook R, Wagner AA, DeWolf WC, Bubley GJ, Funches R, Aronovitz JA, Wei JT, Sanda MG. Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. J Urol 2011; 186:865-72. PubMed
Hide